Mangoceuticals reported cash from operations of -$0.26M and free cash flow of -$0.26M for the quarter ended Jun 2026, up 79.3% year over year. This cash flow statement covers 15 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Net Income | -2.56M | -2.28M | -1.80M | -2.57M | -2.37M | -2.39M | -2.00M | -1.95M | -4.84M | -5.42M | -7.62M | -2.77M | -3.40M | -1.31M | |
| Share-based CompensationStock Comp. | 0.08M | 0.70M | 1.40M | 0.09M | 0.36M | 2.37M | 2.37M | 0.16M | 0.42M | 1.94M | 1.74M | 2.16M | 0.06M | 2.16M | 2.16M |
| Cash from OperationsCash from Ops. | -1.81M | -1.78M | -1.71M | -1.70M | -0.99M | -1.58M | -1.17M | -1.13M | -2.27M | -1.26M | -1.24M | -1.08M | -1.31M | -0.26M | |
| Depreciation, Depletion & Amortization | |||||||||||||||
| Depreciation & Amortization (CF)Dep. & Amort. | 0.01M | 0.01M | 0.01M | 0.00M | 255.00 | 250.00 | 252.00 | 256.00 | |||||||
| Change in Working Capital | |||||||||||||||
| Change in InventoryChange Inventory | -0.00M | -0.00M | -0.00M | -433.00 | -806.00 | ||||||||||
| Change in Account PayablesChange Payables | -0.11M | ||||||||||||||
| Change in Accured ExpensesChange Accured Exp. | -0.01M | 0.11M | -0.04M | 0.05M | 0.88M | -0.30M | -0.01M | 0.13M | 0.34M | 0.09M | -0.64M | -0.00M | 0.11M | 0.36M | |
| Change in TaxesChange Taxes | 0.00M | -0.00M | 0.00M | -0.00M | 893.00 | -0.01M | 0.00M | 0.00M | -0.01M | 0.00M | |||||
| Investing Activities | |||||||||||||||
| Capital ExpendituresCapex | 0.00M | ||||||||||||||
| Cash from Investing ActivitiesCash from Investing | -0.00M | ||||||||||||||
| Financing Activities | |||||||||||||||
| Other financing activitiesOther financing | 0.48M | 0.15M | 0.30M | ||||||||||||
| Cash from Financing ActivitiesCash from Financing | 5.00M | 0.86M | 1.20M | 0.27M | 1.99M | 0.75M | 1.12M | 2.29M | 1.28M | 1.62M | 2.08M | ||||
| Change in Capital Stock | |||||||||||||||
| Net Shares Issued and RepurchasedNet Shares Issued | 1.25M | 0.09M | 0.28M | 0.03M | 2.00M | ||||||||||
| Net Equity Issued and RepurchasedNet Equity Issued | 5.00M | 0.65M | 1.20M | 0.18M | 0.39M | 0.76M | 0.66M | 0.43M | 1.32M | 2.21M | |||||
| Additional items | |||||||||||||||
| Exchange Rate EffectFX Effect | -70.00 | -0.00M | -497.00 | -0.01M | 0.01M | 187.00 | -45.00 | -681.00 | -433.00 | -0.00M | |||||
| Change in Cash | 3.19M | -0.92M | -1.71M | -0.50M | -0.72M | 0.48M | -0.42M | -0.01M | 0.01M | 0.02M | 0.38M | 1.01M | -1.31M | 0.06M | |
| Free Cash FlowFCF | -1.81M | -1.78M | -1.71M | -1.70M | -0.99M | -1.58M | -1.17M | -1.13M | -2.27M | -1.26M | -1.24M | -1.08M | -1.31M | -0.26M | |
| Net Cash FlowNCF | 3.19M | -0.92M | -1.71M | -0.50M | -0.72M | 0.41M | -0.42M | -0.01M | 0.01M | 0.02M | 0.38M | 1.01M | -1.31M | -0.26M |